Scholarly Index
José Baselga
Memorial Sloan Kettering Cancer Center; 116,501 total citations; 727 total publications; best world rank #5
Memorial Sloan Kettering Cancer Center
116,501Total citations
727Total publications
143H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Oncology | Lifetime | 41 | US 23 | 99.93 |
| Pulmonary and Respiratory Medicine | Lifetime | 513 | US 271 | 99.29 |
| Cancer Research | Lifetime | 350 | US 188 | 97.95 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 832 | US 451 | 97.76 |
| HER2/EGFR in Cancer Research | Lifetime | 5 | US 2 | 99.95 |
| Cancer Treatment and Pharmacology | Lifetime | 11 | US 6 | 99.93 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 10 | US 5 | 99.87 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 63 | US 43 | 99.83 |
| Advanced Breast Cancer Therapies | Lifetime | 11 | US 4 | 99.83 |
| Peptidase Inhibition and Analysis | Lifetime | 43 | US 24 | 99.73 |
| Lung Cancer Treatments and Mutations | Lifetime | 139 | US 76 | 99.60 |
| Cancer Genomics and Diagnostics | Lifetime | 296 | US 181 | 99.42 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 514 | US 238 | 98.63 |
| Colorectal Cancer Treatments and Studies | Lifetime | 414 | US 187 | 98.75 |
| Breast Cancer Treatment Studies | Lifetime | 458 | US 223 | 98.62 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 584 | US 237 | 97.20 |
| PARP inhibition in cancer therapy | Lifetime | 866 | US 365 | 91.61 |